Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cost-effectiveness of thiopurine methyltransferase genotype screening in patients about to commence azathioprine therapy for treatment of inflammatory bowel disease.

Alimentary pharmacology & therapeutics - 15 Sept 2004

Winter J, Walker A, Shapiro D, Gaffney D, Spooner R J, Mills P R

Abstract excerpt

BACKGROUND: Azathioprine is a useful agent in the management of inflammatory bowel disease. Its use is limited by its side-effect profile. Marrow toxicity occurs in approximately 3.2% of patients and is known to be associated with diminished thiopurine methyltransferase enzyme activity resulting from genetic polymorphisms. AIM: To evaluate the cost-effectiveness of screening for thiopurine methyltransferase gene...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Azathioprine
Share to Cost-Benefit Analysis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cost of Illness

Share to Genetic Testing

Share to Homozygote

Share to Immunosuppressive Agents

Share to Inflammatory Bowel Diseases

Share to Methyltransferases

Source

Identifiers

PMID: 15352906
DOI: 10.1111/j.1365-2036.2004.02124.x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cost-effectiveness of thiopurine methyltransferase genotype screening in patients about to commence azathioprine therapy for treatment of inflammatory bowel disease.PMID 15352906Read ↗

Assessment of thiopurine methyltransferase enzyme activity is superior to genotype in predicting myelosuppression following azathioprine therapy in patients with inflammatory bowel disease.Semantic proximity Read ↗

The cost-effectiveness of a pharmacogenetic test: a trial-based evaluation of TPMT genotyping for azathioprine.Semantic proximity Read ↗

Risk factors for thiopurine-induced myelosuppression and infections in inflammatory bowel disease patients with a normal TPMT genotype.Semantic proximity Read ↗

Current relevance of pharmacogenetics in immunomodulation treatment for Crohn's disease.Semantic proximity Read ↗

Pharmacoeconomic analyses of azathioprine, methotrexate and prospective pharmacogenetic testing for the management of inflammatory bowel disease.Semantic proximity Read ↗

Avoiding adverse drug reactions by pharmacogenetic testing: a systematic review of the economic evidence in the case of TPMT and AZA-induced side effects.Semantic proximity Read ↗

Prospective evaluation of the pharmacogenetics of azathioprine in the treatment of inflammatory bowel disease.Semantic proximity Read ↗

Thiopurine S-methyltransferase polymorphisms in acute lymphoblastic leukemia, inflammatory bowel disease and autoimmune disorders: influence on treatment responseSemantic proximity Read ↗

Should thiopurine methyltransferase genotypes and phenotypes be measured before thiopurine therapy in patients with inflammatory bowel disease?Semantic proximity Read ↗

Relevance of thiopurine methyltransferase status in rheumatology patients receiving azathioprine.Semantic proximity Read ↗

Cost-effectiveness of pharmacogenomics in clinical practice: a case study of thiopurine methyltransferase genotyping in acute lymphoblastic leukemia in Europe.Semantic proximity Read ↗

Thiopurine methyltransferase activity and the use of azathioprine in inflammatory bowel disease.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.